Aseptic processing and related investigational lapses led the US Food and Drug Administration to issue a warning letter to Takeda Pharmaceutical Co. Ltd. in which the agency questioned whether the company was giving its quality organization the authority and resources required to do its job.
The 9 June warning letter addressed to Takeda CEO Christophe Weber stemmed from an 18-26 November 2019 inspection of...







